Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Market Intelligence United States

‘Rapid Adoption’ Expected For US Humira Biosimilars

AmerisourceBergen’s McGowan Also Sees Oncology Biosimilars Capturing Record Market Share

  • Interviews

Executive Summary

Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Scrip
Generics Bulletin

Topics

Tags:
Biosimilars Market Intelligence United States
Latest Headlines

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results

Lupin Enters Canadian Biosimilars Market With Etanercept

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

See All
UsernamePublicRestriction

Register

GB151458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By